ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 183 filers reported holding ARCUS BIOSCIENCES INC in Q2 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,939,114 | -22.5% | 720,842 | -12.4% | 0.00% | -50.0% |
Q2 2023 | $16,704,407 | +76.5% | 822,472 | +58.5% | 0.00% | +100.0% |
Q1 2023 | $9,466,924 | +16.9% | 519,020 | +32.5% | 0.00% | 0.0% |
Q4 2022 | $8,100,563 | -1.0% | 391,710 | +25.2% | 0.00% | -33.3% |
Q3 2022 | $8,185,000 | -15.5% | 312,901 | -18.1% | 0.00% | 0.0% |
Q2 2022 | $9,683,000 | +13.9% | 382,127 | +41.9% | 0.00% | +50.0% |
Q1 2022 | $8,501,000 | -13.6% | 269,351 | +10.8% | 0.00% | – |
Q4 2021 | $9,838,000 | +110.8% | 243,054 | +81.7% | 0.00% | – |
Q3 2021 | $4,666,000 | -22.1% | 133,787 | -38.7% | 0.00% | – |
Q2 2021 | $5,993,000 | +41.9% | 218,254 | +45.1% | 0.00% | – |
Q1 2021 | $4,223,000 | -42.0% | 150,408 | -46.4% | 0.00% | – |
Q4 2020 | $7,278,000 | +96.9% | 280,434 | +30.1% | 0.00% | – |
Q3 2020 | $3,696,000 | +39.4% | 215,627 | +101.2% | 0.00% | – |
Q2 2020 | $2,651,000 | +1340.8% | 107,158 | +428.6% | 0.00% | – |
Q3 2019 | $184,000 | -22.7% | 20,271 | -32.1% | 0.00% | – |
Q2 2019 | $238,000 | – | 29,842 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |